Pub Date : 2024-06-12DOI: 10.30683/1927-7229.2024.13.02
M. J. Gonzalez, J. Miranda-Massari, M. J. Gonzalez, J. Olalde, Miguel J. Berdiel, Liza Cardona
Hypoxia is a critical characteristic of malignant tumors and involves enhanced cell survival, angiogenesis, glycolytic metabolism, and metastasis. Hyperbaric oxygen treatment (HBOT) has been used to improve and cure disorders involving hypoxia and ischemia, HBOT enhances the amount of dissolved oxygen in the plasma and thereby increasing O2 delivery to the tissue. Studies on HBOT and cancer have mostly focused on whether enhanced oxygen may act as a promoter of cancer. As oxygen is believed to be required for all the major processes of wound healing, including angiogenesis, this particular idea would give the impression that HBOT will promote cancer growth and recurrence. Nevertheless, this is not the case since the use of HBOT in patients with malignancies should be considered safe and therapeutic. There is no evidence indicating that HBO neither acts as a stimulator of tumor growth nor as an enhancer of recurrence. On the other hand, there is evidence that implies that HBO has tumor-inhibitory effects, this manuscript pretends to expand our knowledge on the effect and the mechanisms behind tumor oxygenation by HBOT.
{"title":"New Insights on Hyperbaric Oxygen Therapy for Cancer","authors":"M. J. Gonzalez, J. Miranda-Massari, M. J. Gonzalez, J. Olalde, Miguel J. Berdiel, Liza Cardona","doi":"10.30683/1927-7229.2024.13.02","DOIUrl":"https://doi.org/10.30683/1927-7229.2024.13.02","url":null,"abstract":"Hypoxia is a critical characteristic of malignant tumors and involves enhanced cell survival, angiogenesis, glycolytic metabolism, and metastasis. Hyperbaric oxygen treatment (HBOT) has been used to improve and cure disorders involving hypoxia and ischemia, HBOT enhances the amount of dissolved oxygen in the plasma and thereby increasing O2 delivery to the tissue. Studies on HBOT and cancer have mostly focused on whether enhanced oxygen may act as a promoter of cancer. As oxygen is believed to be required for all the major processes of wound healing, including angiogenesis, this particular idea would give the impression that HBOT will promote cancer growth and recurrence. Nevertheless, this is not the case since the use of HBOT in patients with malignancies should be considered safe and therapeutic. There is no evidence indicating that HBO neither acts as a stimulator of tumor growth nor as an enhancer of recurrence. On the other hand, there is evidence that implies that HBO has tumor-inhibitory effects, this manuscript pretends to expand our knowledge on the effect and the mechanisms behind tumor oxygenation by HBOT.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"118 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141351780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-22DOI: 10.30683/1927-7229.2024.13.01
A. Leskanicova, P. Simko, M. Babinčák, A. Blicharova, M. Kertys, J. Kostolný, D. Maceková, T. Kiskova
Malignant gliomas are one of the most treatment-refractory cancers. Development of resistance to chemo- and radiotherapies contributes to these tumors’ aggressive phenotypes. Elevated lipid levels in gliomas have been reported for the last 50 years. However, the molecular mechanisms of how tumor tissues obtain lipids and utilize them are not well understood.In our study, 48.6% of phosphatidylcholines were significantly changed during an early stage of brain cancer in females, and 66.2% in males. As for lysophosphatidylcholines 57.1% metabolites were significantly changed in female, and 64.3% in male rats. We observed the most interesting results in the group of sphingomyelins, where 85.8% metabolites were significantly elevated during brain cancer. According to VIP projection, the most important metabolites were: PC ae C40:3, PC ae C38:1, PC ae C30:1, PC ae C38:3, PC ae C44:3, PC aa C40:2, PC aa C42:0, PC ae C30:2, SM C20:2, PC aa C42:1 in females, and PC ae C38:1, PC ae C40:3, PC ae C30:1, PC ae C42:1, SM C20:2, PC aa C34:4, PC ae C38:4, PC aa C32:2, PC aa C38:5, lysoPC a C14:0. The identification of lipid biomarkers during the early stage of cancer could improve patient prognosis.
恶性胶质瘤是最难治疗的癌症之一。对化疗和放疗产生抗药性是这些肿瘤具有侵袭性表型的原因之一。过去 50 年来，胶质瘤中脂质水平升高的报道屡见不鲜。在我们的研究中，48.6%的磷脂酰胆碱在女性脑癌早期发生了显著变化，而在男性中则为 66.2%。至于溶血磷脂酰胆碱，57.1%的代谢物在雌性大鼠和 64.3%的雄性大鼠中发生了明显变化。我们在鞘磷脂组观察到了最有趣的结果，其中 85.8%的代谢物在脑癌期间明显升高。根据 VIP 预测，最重要的代谢物是PC ae C40:3、PC ae C38:1、PC ae C30:1、PC ae C38:3、PC ae C44:3、PC aa C40:2、PC aa C42:0、PC ae C30:2、SM C20:2、PC aa C42：雌性为 PC ae C38:1、PC ae C40:3、PC ae C30:1、PC ae C42:1、SM C20:2、PC aa C34:4、PC ae C38:4、PC aa C32:2、PC aa C38:5、溶菌酶PC a C14:0。在癌症早期识别脂质生物标志物可改善患者的预后。
{"title":"Chemically Induced Brain Cancer in Sprague-Dawley Rats: Changed Lipidomics Mimics the Human Conditions","authors":"A. Leskanicova, P. Simko, M. Babinčák, A. Blicharova, M. Kertys, J. Kostolný, D. Maceková, T. Kiskova","doi":"10.30683/1927-7229.2024.13.01","DOIUrl":"https://doi.org/10.30683/1927-7229.2024.13.01","url":null,"abstract":"Malignant gliomas are one of the most treatment-refractory cancers. Development of resistance to chemo- and radiotherapies contributes to these tumors’ aggressive phenotypes. Elevated lipid levels in gliomas have been reported for the last 50 years. However, the molecular mechanisms of how tumor tissues obtain lipids and utilize them are not well understood.In our study, 48.6% of phosphatidylcholines were significantly changed during an early stage of brain cancer in females, and 66.2% in males. As for lysophosphatidylcholines 57.1% metabolites were significantly changed in female, and 64.3% in male rats. We observed the most interesting results in the group of sphingomyelins, where 85.8% metabolites were significantly elevated during brain cancer. According to VIP projection, the most important metabolites were: PC ae C40:3, PC ae C38:1, PC ae C30:1, PC ae C38:3, PC ae C44:3, PC aa C40:2, PC aa C42:0, PC ae C30:2, SM C20:2, PC aa C42:1 in females, and PC ae C38:1, PC ae C40:3, PC ae C30:1, PC ae C42:1, SM C20:2, PC aa C34:4, PC ae C38:4, PC aa C32:2, PC aa C38:5, lysoPC a C14:0. The identification of lipid biomarkers during the early stage of cancer could improve patient prognosis.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"78 21","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140675301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-11DOI: 10.30683/1927-7229.2023.12.09
Sajad Ahmad Salati, Amjaad Alkhezzi, Mohammad Ahmed Elmuttalut, Muhammad Munir Memon, Mushhood Memon
Two or more histologically distinct malignancies in one individual are termed as multiple primary malignant tumours (MPMT). The incidence of these cases has been rising over the past few decades, primarily due to improved methods for cancer screening, diagnosis, treatment, and follow-up. They can show up as metachronous lesions later on or synchronously with the index malignancy. The precise aetiology is still unknown; however, a number of epidemiological variables have been proposed as potential risk factors. Modern imaging techniques are very helpful in the diagnosing process. Physician awareness is essential in order to raise suspicions about the potential for MPMT and to conduct appropriate investigations. There are currently no universal protocols based on evidence; instead, management is empirical and dependent on the judgments made by interdisciplinary teams.
{"title":"Multiple Primary Malignant Tumours","authors":"Sajad Ahmad Salati, Amjaad Alkhezzi, Mohammad Ahmed Elmuttalut, Muhammad Munir Memon, Mushhood Memon","doi":"10.30683/1927-7229.2023.12.09","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.09","url":null,"abstract":"Two or more histologically distinct malignancies in one individual are termed as multiple primary malignant tumours (MPMT). The incidence of these cases has been rising over the past few decades, primarily due to improved methods for cancer screening, diagnosis, treatment, and follow-up. They can show up as metachronous lesions later on or synchronously with the index malignancy. The precise aetiology is still unknown; however, a number of epidemiological variables have been proposed as potential risk factors. Modern imaging techniques are very helpful in the diagnosing process. Physician awareness is essential in order to raise suspicions about the potential for MPMT and to conduct appropriate investigations. There are currently no universal protocols based on evidence; instead, management is empirical and dependent on the judgments made by interdisciplinary teams.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"79 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138979439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The purpose of this publication is not to state the fact of the high antitumor effectiveness of the gold standard treatment of malignant brain tumors (surgical intervention with adjuvant chemoradiotherapy), but to consider the possibility of using alternative therapeutic options, in particular, magnetotherapy, as a component of the treatment of patients with this serious pathology, as well as a method of preventing a number of postoperative adverse reactions.
{"title":"Magnetotherapy in Experimental and Clinical Neuro-Oncology: A Review","authors":"F.F. Borichevsky, I.S. Lioubichtchev, A.E. Sahun, A.S. Trus, D.A. Tzerkovsky","doi":"10.30683/1927-7229.2023.12.08","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.08","url":null,"abstract":"The purpose of this publication is not to state the fact of the high antitumor effectiveness of the gold standard treatment of malignant brain tumors (surgical intervention with adjuvant chemoradiotherapy), but to consider the possibility of using alternative therapeutic options, in particular, magnetotherapy, as a component of the treatment of patients with this serious pathology, as well as a method of preventing a number of postoperative adverse reactions.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"267 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136012605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-10DOI: 10.30683/1927-7229.2023.12.07
Sajad Ahmad Salati, Mohammed Alfehaid, Lamees AlSulaim, S. Alsuwaydani, M. Elmuttalut
Breast cancer can metastasize to a wide range of organs, but reports about uterine metastases are rare. The current article systematically analyzes 55 patients reported in peer-reviewed literature from 2010–2022 with respect to nine variables, including: [i] age of the patient; [ii] clinical presentation of uterine metastasis; [iii] precise location of metastasis; [iv] primary (breast) cancer histopathology; [v] imaging modality utilized for detection of metastasis; [vi] timing of appearance of metastases: synchronous or metachronous; [vii] immunochemistry markers; [viii] management; and [ix] survival. Uterine metastases may appear in synchronous or metachronous fashion and may be asymptomatic or have symptoms like abnormal vaginal bleeding. Treatment of uterine metastases usually comprises of total abdominal hysterectomy with bilateral salpingo-oophorectomy along with chemotherapy. The long-term prognosis is unclear, but due to the development of metastases in other bodily parts, cases frequently have a poor outcome.
{"title":"Uterine Metastasis from Carcinoma of Breast – A Systematic Analysis","authors":"Sajad Ahmad Salati, Mohammed Alfehaid, Lamees AlSulaim, S. Alsuwaydani, M. Elmuttalut","doi":"10.30683/1927-7229.2023.12.07","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.07","url":null,"abstract":"Breast cancer can metastasize to a wide range of organs, but reports about uterine metastases are rare. The current article systematically analyzes 55 patients reported in peer-reviewed literature from 2010–2022 with respect to nine variables, including: [i] age of the patient; [ii] clinical presentation of uterine metastasis; [iii] precise location of metastasis; [iv] primary (breast) cancer histopathology; [v] imaging modality utilized for detection of metastasis; [vi] timing of appearance of metastases: synchronous or metachronous; [vii] immunochemistry markers; [viii] management; and [ix] survival. Uterine metastases may appear in synchronous or metachronous fashion and may be asymptomatic or have symptoms like abnormal vaginal bleeding. Treatment of uterine metastases usually comprises of total abdominal hysterectomy with bilateral salpingo-oophorectomy along with chemotherapy. The long-term prognosis is unclear, but due to the development of metastases in other bodily parts, cases frequently have a poor outcome.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89642531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-10DOI: 10.30683/1927-7229.2023.12.06
Karen Reyes, G. Verbeck
True One Cell (TOC) analysis Is becoming highly critical for functional studies of cancer cells. This is partially because it is the only form of analysis that provides an avenue for studying the heterogeneity and cell-to-cell variations of individual cancer cells, thus providing unique insight into complex regulatory processes that govern TOC functions within a tumor. Additionally, true one cell techniques are playing an increasingly important role in current attempts to implement TOC metabolomic and proteomic studies, as well as emerging attempts to spatially resolve TOC information. In this review we provide a brief overview of the basis of the field and discuss its applications in TOC metabolomics and proteomics.
{"title":"True One Cell Chemical Analysis in Cancer Research: A Review","authors":"Karen Reyes, G. Verbeck","doi":"10.30683/1927-7229.2023.12.06","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.06","url":null,"abstract":"True One Cell (TOC) analysis Is becoming highly critical for functional studies of cancer cells. This is partially because it is the only form of analysis that provides an avenue for studying the heterogeneity and cell-to-cell variations of individual cancer cells, thus providing unique insight into complex regulatory processes that govern TOC functions within a tumor. Additionally, true one cell techniques are playing an increasingly important role in current attempts to implement TOC metabolomic and proteomic studies, as well as emerging attempts to spatially resolve TOC information. In this review we provide a brief overview of the basis of the field and discuss its applications in TOC metabolomics and proteomics.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89741320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01DOI: 10.30683/1927-7229.2023.12.05
M. Auber, S. Wen, Francesca Farran, G. Higa
Introduction: Deaths due to colorectal cancer are disproportionately higher than either breast or prostate cancers even though the majority of new cases are potentially curable at diagnoses. If only half of the losses is due to metastatic disease at diagnosis, then a share of the remaining deaths must be attributable to tumor recurrence after presumptively curative therapy of early-stage disease. If so, current management of the latter group is suboptimal for a considerable number of subjects, a perception which argues for an assessment of maintenance therapy. Moreover, most recurrences occur within 24 months after standard surgical and (neo)adjuvant therapies. Objective: To assess relapse-free and overall survival among patients with high-risk, resected tumors who did and did not receive maintenance therapy following completion of treatment according to accepted guidelines. Methods: Pertinent clinical details were collected on 85 subjects, 37 who were, and 48 who were not, treated with maintenance therapy. Descriptive statistical analyses related to survival outcomes were performed on accumulated data. Wilcoxon rank test and Fisher’s exact test were used to examine the continuous and categorical variables, respectively. Kaplan-Meier method and log-rank test were used to analyze between-group relapse-free and overall survival. Results: Of the entire cohort, 63 of 85 (74.1%) subjects have no evidence of disease, a median of 5 years from the end of adjuvant therapy. Kaplan-Meier analyses indicated statistically, but not necessarily clinically, non-significant differences in median 5-year relapse-free survival, 79.8% vs 69.2%, and overall survival, 87.8% vs 81.7% in the treated and untreated groups of patients, respectively. A total of 21 subjects died; three of seven (treated group) and all 14 (untreated group) due to cancer. Conclusion: Obscured is the hint that maintenance therapy is clinically more effective than what the p-value intimates. The results of this retrospective data collection and analyses suggest that some patients with early-stage, high-risk disease, will derive survival benefits with maintenance therapy.
导读:结直肠癌的死亡率比乳腺癌或前列腺癌高得多，尽管大多数新病例在诊断时是可以治愈的。如果只有一半的死亡是由于诊断时的转移性疾病，那么其余的一部分死亡必须归因于早期疾病的推定治愈治疗后的肿瘤复发。如果是这样的话，对于相当多的受试者来说，后一组的当前管理是次优的，这一观点主张对维持治疗进行评估。此外，大多数复发发生在标准手术和(新)辅助治疗后的24个月内。目的:评估高风险切除肿瘤患者在按照公认的指南完成治疗后接受和未接受维持治疗的无复发生存期和总生存期。方法:收集85例患者的相关临床资料，其中37例接受维持治疗，48例未接受维持治疗。对累积的数据进行与生存结果相关的描述性统计分析。分别采用Wilcoxon秩检验和Fisher精确检验对连续变量和分类变量进行检验。采用Kaplan-Meier法和log-rank检验分析组间无复发生存率和总生存率。结果:在整个队列中，85名受试者中有63名(74.1%)没有疾病证据，中位时间为辅助治疗结束后5年。Kaplan-Meier分析显示，治疗组和未治疗组患者的5年无复发生存中位数(79.8% vs 69.2%)和总生存中位数(87.8% vs 81.7%)在统计学上(但不一定是临床)无显著差异。共有21名受试者死亡;7人中的3人(治疗组)和全部14人(未治疗组)死于癌症。结论:维持治疗在临床上比p值更有效的提示被掩盖了。这项回顾性数据收集和分析的结果表明，一些早期、高风险疾病的患者通过维持治疗将获得生存益处。
{"title":"Survival Outcomes in High-Risk, Resected Colorectal Cancer with and without Maintenance Therapy","authors":"M. Auber, S. Wen, Francesca Farran, G. Higa","doi":"10.30683/1927-7229.2023.12.05","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.05","url":null,"abstract":"Introduction: Deaths due to colorectal cancer are disproportionately higher than either breast or prostate cancers even though the majority of new cases are potentially curable at diagnoses. If only half of the losses is due to metastatic disease at diagnosis, then a share of the remaining deaths must be attributable to tumor recurrence after presumptively curative therapy of early-stage disease. If so, current management of the latter group is suboptimal for a considerable number of subjects, a perception which argues for an assessment of maintenance therapy. Moreover, most recurrences occur within 24 months after standard surgical and (neo)adjuvant therapies. \u0000Objective: To assess relapse-free and overall survival among patients with high-risk, resected tumors who did and did not receive maintenance therapy following completion of treatment according to accepted guidelines. \u0000Methods: Pertinent clinical details were collected on 85 subjects, 37 who were, and 48 who were not, treated with maintenance therapy. Descriptive statistical analyses related to survival outcomes were performed on accumulated data. Wilcoxon rank test and Fisher’s exact test were used to examine the continuous and categorical variables, respectively. Kaplan-Meier method and log-rank test were used to analyze between-group relapse-free and overall survival. \u0000Results: Of the entire cohort, 63 of 85 (74.1%) subjects have no evidence of disease, a median of 5 years from the end of adjuvant therapy. Kaplan-Meier analyses indicated statistically, but not necessarily clinically, non-significant differences in median 5-year relapse-free survival, 79.8% vs 69.2%, and overall survival, 87.8% vs 81.7% in the treated and untreated groups of patients, respectively. A total of 21 subjects died; three of seven (treated group) and all 14 (untreated group) due to cancer. \u0000Conclusion: Obscured is the hint that maintenance therapy is clinically more effective than what the p-value intimates. The results of this retrospective data collection and analyses suggest that some patients with early-stage, high-risk disease, will derive survival benefits with maintenance therapy.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88920629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-03DOI: 10.30683/1927-7229.2023.12.03
T. Artsemyeva, D. Tzerkovsky
The aim of this study is to evaluate a safety and antitumor efficacy of photodynamic therapy (PDT) with chlorine-based photosensitizer (PS) for treatment patients with basal cell skin carcinomas (BCC). Material and Methods: The work was performed on the basis of the Department of hyperthermia and photodynamic therapy. The object of the study were 172 patients with a verified diagnosis of BCC (T1N0M0, I stage), who received treatment from 2007 to 2022. PS «Photolon» (RUE «Belmedpreparaty», Republic of Belarus) was administrated intravenously at a dose of 2.0-2.5 mg/kg. The session of PDT was performed 2.5-3 h after intravenous injection of PS using semiconductor lasers (λ=660±5 nm) with exposure doses 50-250 J/cm² and power density – 0.15-0.5 W/cm². Frequency and severity of side effects after treatment session was assessed based on the criteria CTCAE (Version 4.03; 2010). The antitumor efficacy was evaluated 3 months after treatment. Clinical outcome was evaluated visually and morphologically by cytological or histopathological examination. Performance criteria were as follows (according to WHO, 1979). Results: The phenomenon of skin phototoxicity due to violation of the light regime (hyperemia, burning, slight swelling of the soft tissues of the face; CTCAE, I-II grades) was registered in 5.8% of cases (n=10). Serious adverse reactions (anaphylactic shock, Quincke's edema, severe pain syndrome) after the administration of PS and photoirradiation were not identified. Complete and partial regressions of tumors was observed in 93.0% and 4.7% of patients, respectively. The objective answer was 97.7%. The frequency of local relapses of the disease 1, 2, 3, 4 and 5 years after PDT was 3.1%, 3.1%, 4.6%, 4.6% and 6.9%, respectively. Сonclusion: PDT is a well-tolerated and highly effective therapeutic option in patients with BCC.
{"title":"Efficacy of Photodynamic Therapy with Chlorine-Based Photosensitizer in the Treatment of Basal Cell Carcinomas","authors":"T. Artsemyeva, D. Tzerkovsky","doi":"10.30683/1927-7229.2023.12.03","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.03","url":null,"abstract":"The aim of this study is to evaluate a safety and antitumor efficacy of photodynamic therapy (PDT) with chlorine-based photosensitizer (PS) for treatment patients with basal cell skin carcinomas (BCC). \u0000Material and Methods: The work was performed on the basis of the Department of hyperthermia and photodynamic therapy. The object of the study were 172 patients with a verified diagnosis of BCC (T1N0M0, I stage), who received treatment from 2007 to 2022. PS «Photolon» (RUE «Belmedpreparaty», Republic of Belarus) was administrated intravenously at a dose of 2.0-2.5 mg/kg. The session of PDT was performed 2.5-3 h after intravenous injection of PS using semiconductor lasers (λ=660±5 nm) with exposure doses 50-250 J/cm² and power density – 0.15-0.5 W/cm². Frequency and severity of side effects after treatment session was assessed based on the criteria CTCAE (Version 4.03; 2010). The antitumor efficacy was evaluated 3 months after treatment. Clinical outcome was evaluated visually and morphologically by cytological or histopathological examination. Performance criteria were as follows (according to WHO, 1979). \u0000Results: The phenomenon of skin phototoxicity due to violation of the light regime (hyperemia, burning, slight swelling of the soft tissues of the face; CTCAE, I-II grades) was registered in 5.8% of cases (n=10). Serious adverse reactions (anaphylactic shock, Quincke's edema, severe pain syndrome) after the administration of PS and photoirradiation were not identified. Complete and partial regressions of tumors was observed in 93.0% and 4.7% of patients, respectively. The objective answer was 97.7%. The frequency of local relapses of the disease 1, 2, 3, 4 and 5 years after PDT was 3.1%, 3.1%, 4.6%, 4.6% and 6.9%, respectively. \u0000Сonclusion: PDT is a well-tolerated and highly effective therapeutic option in patients with BCC.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81976246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-03DOI: 10.30683/1927-7229.2023.12.04
Sajad Ahmad Salati, S. Alsuwaydani
Virchow-Troisier's node is an eponymous term referring to the enlargement of the left supraclavicular lymph node. It is a significant physical finding that generally indicates the late manifestation of a variety of malignancies. This review article briefly revisits the historical background, epidemiology, anatomical routes of metastasis, clinical presentation, differential diagnosis, and clinical significance of Virchow-Troisier's node.
{"title":"Virchow-Troisier's Node: A Review","authors":"Sajad Ahmad Salati, S. Alsuwaydani","doi":"10.30683/1927-7229.2023.12.04","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.04","url":null,"abstract":"Virchow-Troisier's node is an eponymous term referring to the enlargement of the left supraclavicular lymph node. It is a significant physical finding that generally indicates the late manifestation of a variety of malignancies. This review article briefly revisits the historical background, epidemiology, anatomical routes of metastasis, clinical presentation, differential diagnosis, and clinical significance of Virchow-Troisier's node.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"330 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76575795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-08DOI: 10.30683/1927-7229.2023.12.02
Sajad Ahmad Salati, Lamees AlSulaim
Sister Mary Joseph Nodule is an eponymous term referring to an umbilical nodule harbouring malignant metastatic cancer. It is a physical finding that is uncommon yet significant since it indicates the late manifestation of a variety of deep-seated abdominopelvic malignancies. This review article briefly revisits the historical background, epidemiology, anatomical routes of metastasis, clinical presentation, differential diagnosis, diagnostic work-up, clinical significance and prognosis of Sister Mary Joseph’s nodule.
{"title":"Sister Mary Joseph Nodule (SMJN) – A Review","authors":"Sajad Ahmad Salati, Lamees AlSulaim","doi":"10.30683/1927-7229.2023.12.02","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.02","url":null,"abstract":"Sister Mary Joseph Nodule is an eponymous term referring to an umbilical nodule harbouring malignant metastatic cancer. It is a physical finding that is uncommon yet significant since it indicates the late manifestation of a variety of deep-seated abdominopelvic malignancies. This review article briefly revisits the historical background, epidemiology, anatomical routes of metastasis, clinical presentation, differential diagnosis, diagnostic work-up, clinical significance and prognosis of Sister Mary Joseph’s nodule.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74180162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：